Biomarkers for differentiating grade II meningiomas from grade I: a systematic review-Reference-Cited by-同舟云学术

Biomarkers for differentiating grade II meningiomas from grade I: a systematic review

Published:2021-06-21 Issue:6 Volume:35 Page:696-702
ISSN:0268-8697
Container-title:British Journal of Neurosurgery
language:en
Short-container-title:British Journal of Neurosurgery

Author:

Sofela Agbolahan A.¹²^ORCID,McGavin Lucy³,Whitfield Peter C.²,Hanemann C. Oliver¹

Affiliation:

1. Faculty of Health: Medicine, Dentistry and Human Sciences, The Institute of Translational and Stratified Medicine, University of Plymouth, Plymouth, UK

2. South West Neurosurgery Centre, University Hospitals Plymouth NHS Trust, Plymouth, UK

3. Department of Radiology, Derriford Hospital, Plymouth, UK

Publisher

Informa UK Limited

Subject

Neurology (clinical),General Medicine,Surgery

Link

https://www.tandfonline.com/doi/pdf/10.1080/02688697.2021.1940853

Reference84 articles.

1. Evaluation of autoantibody signatures in meningioma patients using human proteome arrays

2. Targeted drug therapy for meningiomas

3. Accuracy of Radiomics-Based Feature Analysis on Multiparametric Magnetic Resonance Images for Noninvasive Meningioma Grading

4. Multiplatform genomic profiling and magnetic resonance imaging identify mechanisms underlying intratumor heterogeneity in meningioma

5. Circulating Tumor Biomarkers in Meningiomas Reveal a Signature of Equilibrium Between Tumor Growth and Immune Modulation

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biomarkers for prognosis of meningioma patients: A systematic review and meta-analysis;PLOS ONE;2024-05-17

2. Advances in Mass Spectrometry of Gangliosides Expressed in Brain Cancers;International Journal of Molecular Sciences;2024-01-22

3. Unveiling a Biomarker Signature of Meningioma: The Need for a Panel of Genomic, Epigenetic, Proteomic, and RNA Biomarkers to Advance Diagnosis and Prognosis;Cancers;2023-11-09

4. Loss of H3K27me3 expression enriches in recurrent grade 1&2 meningiomas and maintains as a biomarker stratifying progression risk;Journal of Neuro-Oncology;2022-11-03

5. Dissecting Stemness in Aggressive Intracranial Meningiomas: Prognostic Role of SOX2 Expression;International Journal of Molecular Sciences;2022-10-02